drug approval catalyst

Biotech stocks often exhibit immediate volatility following recent FDA approvals, reflecting the market’s sensitivity to regulatory inflection points. For publicly traded life sciences companies in the United States, a new drug or biologic approval can rapidly alter revenue projections, partnership dynamics, and long-term valuation models. However, equity reactions are rarely uniform. Institutional investors, hedge funds, … Read more